The Native Antigen Company Joins LGC

MILFORD, Massachusetts, July 9, 2020 –

LGC, the UK based global leader in the life sciences sector has acquired the business of Oxford-based The Native Antigen Company (“NAC”), one of the world’s leading suppliers of high-quality infectious disease antigens and antibodies.

As a result of the acquisition, NAC will become part of the Clinical Diagnostics Division within LGC. NAC’s business operation will continue in Oxford, UK.

NAC’s founder and COO Nick Roesen and Commercial Director Andy Lane will continue in their key roles with NAC following the transaction.

NAC is a developer, manufacturer and supplier of critical reagents to the in vitro diagnostic (IVD), pharmaceutical and academic sectors. It offers a comprehensive portfolio of native and recombinant infectious disease antigens and related products including pathogen receptors, virus-like particles and antibodies for use in immunoassay applications, vaccine development and quality control solutions. NAC was one of the first companies globally to offer antigens for SARS-COV-2 and continues to play an important role in supporting the global response to the COVID-19 pandemic.

The acquisition strengthens LGC’s existing product offering to the IVD sector, which includes a range of quality reference and measurement tools for assay development in serology, molecular, clinical chemistry, immunochemistry and clinical genomics diagnostics.

Michael Sweatt, Executive Vice President and General Manager, Clinical Diagnostics, LGC, said, “NAC is a natural fit with our clinical diagnostics business and will enable us to provide an expanded portfolio of critical reagents to our customers. NAC’s focus on infectious disease is highly complementary with our existing offer to this segment comprising controls, reference materials, molecular diagnostic tools and other components. We are excited to welcome our new colleagues into our organisation.”

“We are delighted to be joining LGC as an integral part of their fast growing clinical diagnostics business.“ said Nick Roesen, COO of NAC. “Even more so, we are excited to join such a well-respected organisation that shares our purpose and mission, and that will support our diagnostic customers by providing even more world-leading products and services.”

For more information please reach out to:

Greg Ballish, SVP, Commercial, LGC Clinical Diagnostics
Tel +1 508 801 1035
Email gregory.ballish@lgcgroup.com

Or

Andy Lane, Commercial Director, NAC
Tel +44 1865 595230
Email alane@thenativeantigencompany.com